The Impact of Late Effects After Treatment for Bladder Cancer on Quality of Life

Bladder Cancer Clinical Trial

— CONQUER  

Official title:

The Impact of Late Effects After Treatment for Bladder Cancer on Quality of Life - What is the Cost of the Cure?

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05195515
• Other study ID #: CONQUER
• Status: Enrolling by invitation
• Start date: January 1, 2022
• Est. completion date: December 31, 2027

Study information

• Verified date: July 2023
• Source: Aarhus University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Bladder Cancer prognosis, treatment, and subsequent morbidity and mortality vary between the different stages, thus resulting in a different impact on patients' lives. There are some well known late effects of the treatments for bladder cancer, but the knowledge of their impact on patients Quality of Life is sparse. This study aims to determine the prevalence of late effects impact on Quality of Life and potential risk factors for impairment.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 2000
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients are eligible if they are referred to a hospital in the Central Region Denmark, due to hematuria between 01/01/2022 and 01/01/2023

• Ability to understand written and oral Danish

Exclusion Criteria:

• Known Alzheimers disease

• Diagnosed other causes explaining the hematuria

Related Conditions & MeSH terms

• Bladder Cancer
• Urinary Bladder Neoplasms

Locations

Country	Name	City	State
Denmark	Department of Urology, Aarhus University Hospital	Aarhus N
Denmark	Department of Urology, Regional Hospital Gødstrup	Gødstrup
Denmark	Department of Urology, Regional Hospital Horsens	Horsens
Denmark	Department of Urology, Regional Hospital Randers	Randers
Denmark	Department of Urology, Regional Hospital Viborg	Viborg

Sponsors (3)

Lead Sponsor	Collaborator
Aarhus University Hospital	Aarhus University, Institute of Clinical Medicine, National Research Center for Survivorship and Late Adverse Effects Following Pelvic Organ Cancer, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Health-related Quality of Life	Changes in Quality of Life measured using validated instruments	5 years from baseline inclusion
Secondary	Prevalence of late effects	Based on Patient Reported Outcomes and medical records	5 years from baseline inclusion